SCHEMBL24257739

SCHEMBL24257739

Cc1c(-c2ccc3ncccc3c2)cnc(C#N)c1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ADORA2A P29274 4/20 0.47
ALDH1A1 P00352 1/20 0.42
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
DYRK1A Q13627 1/20 0.41
TGFBR1 P36897 4/20 0.41
TGFBR2 P37173 1/20 0.41
CCNC P24863 1/20 0.39
CDK8 P49336 1/20 0.39
GRM1 Q13255 1/20 0.38
AR P10275 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546884 1.00 POLB (0.48) POLBNPC1RAB9AADORA2AALDH1A1
SCHEMBL24257623 0.85 DHFR (0.43) POLBADORA2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL30546851 0.85 DHFR (0.43) POLBADORA2AALDH1A1SMN1; SMN2CYP1A2
SCHEMBL30453344 0.84 CYP1A2 (0.39) POLBCYP1A2
SCHEMBL24257719 0.84 CYP1A2 (0.39) POLBCYP1A2
SCHEMBL24257735 0.79 ALOX15 (0.48) ARCYP1A2CYP3A4CYP2C19CYP11B2
SCHEMBL24257731 0.77 LRRK2 (0.42) POLBNPC1RAB9AADORA2AALDH1A1
SCHEMBL24257695 0.77 KDM4E (0.45) ALDH1A1MAPK1SMN1; SMN2CYP1A2CYP3A4
SCHEMBL24257698 0.77 DHFR (0.44) NPC1RAB9AADORA2AALDH1A1SMN1; SMN2
SCHEMBL30454648 0.77 DHFR (0.44) NPC1RAB9AADORA2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 POLB 3169/4885NPC1 4011/4885RAB9A 739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.